TO THE EDITOR:
A 63-year-old woman presented with polyuria, polydipsia, lethargy and vomiting. Two weeks previously, she had been diagnosed as having diffuse scleroderma with possible interstitial lung disease, and had started taking 50 mg prednisolone daily. Her past history included diabetes, hypertension, hypercholesterolaemia and β-thalassemia trait, and her other medications were metformin, glibenclamide, quinapril and amlodipine.
Examination revealed blood pressure 150/60 mmHg, a loud second heart sound with no murmurs, and late inspiratory crepitations at lung bases. Her serum creatinine concentration was 270 mol/L (compared with 100 mol/L two weeks previously) and serum glucose concentration was 26.5 mmol/L. Treatment by the admitting doctor included insulin, rehydration, and cessation of prednisolone (given hyperglycaemia) and quinapril (secondary to acute renal impairment). She developed a fever and cough, with bilateral pneumonia, which was treated with intravenous ceftriaxone.
Despite normotension, concern regarding scleroderma renal crisis (SRC) was raised. On Day 12 of admission, when renal failure had developed to the dialysisdependent level (serum creatinine level, 690 mol/L), quinapril was recommenced for its proposed renoprotective effect and haemodialysis was initiated. Microangiopathic haemolytic anaemia (haemoglobin, 7.2 g/L) was diagnosed, with fragmented red blood cells (Box).
Several months later, she continues on haemodialysis three times a week. Renal biopsy was not performed given the clinical picture of diffuse scleroderma and recent corticosteroid use with rapid development of renal failure -consistent with SRC.
SRC is defined as rapidly progressive renal failure and/or new onset of malignant hypertension during the course of scleroderma, occurring in 15%-20% of patients with the diffuse variety. 1 Risk factors include male sex, black race, and early diffuse scleroderma with rapidly progressive skin thickening. 2 Precipitation of SRC by corticosteroid use, especially in normotensive patients, is well described, particularly with high-dose (>15 mg/day) treatment. 2 Early diagnosis is critical because treatment may preserve renal function. 3 Outcomes have improved with use of angiotensin-converting enzyme (ACE) inhibitors, 2 which are thought to improve renal function by controlling the high renin levels seen in patients with SRC. About 61% of patients have a good outcome, with no or temporary dialysis. 3 Predictors of poor outcome, despite ACE inhibitor use, include older age, male sex, higher initial serum creatinine level, and scleroderma myocardial disease.
1 Eleven per cent of SRC patients remain normotensive and have significantly reduced 12-month survival rates. 4 This may relate to delay in diagnosis of SRC. 
Comprehensive care has been shown to improve outcome in asthma management when it has four components -asthma education, self-monitoring, written self-management plans, and regular medical review. 1, 2 A recent Cochrane Review has explored the role of one of these componentswritten self-management plans -and concluded that there is "no consistent evidence that written plans produced better patient outcomes". 3 Should this cause us to change our management strategies in Australian general practice? Does this mean that our patients are not able to care for their own asthma without our intensive assistance?
These findings update a 1998 review of the role of written asthma management plans as part of comprehensive care in 1998: "In five studies which compared subjects who managed their asthma by selfadjustment according to individualised written plan with those whose medications were adjusted by the doctor, lung function data (FEV 1 [forced expiratory volume in one second] and PEF [peak expiratory flow]) were significantly higher in the selfmanaged group." 1 In Australian general practice, between 30% and 50% of patients are given a written asthma management plan. 4 These plans form part of known beneficial comprehensive asthma care plans, such as the Six-Step Asthma Management Plan 5 or the Asthma 3+ Visit Plan. 4 
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Changes of thalassaemia (microcytosis and hypochromasia) and microangiopathic haemolysis (fragmented red cells and spherocytes). 1. Spherocytes. 2. Fragmented red blood cells.
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The small number of available high quality trials for this most recent review led the authors to say, "Available trials are too small and the results too inconsistent to form any firm conclusions", and suggests that more trials are needed to produce a conclusive result. 3 We should be careful not to lose the positive effects of improved chronic disease management in asthma by over-responding to this one review of one component of comprehensive care. 
COMMENT:
A Cochrane systematic review identified the beneficial effects of planned asthma management and education that includes a written action plan. 1 These findings have now been adapted for primary care and implemented as the Asthma 3+ Visit Plan. This involves a systematic assessment of asthma symptoms, lung function, and current treatment at each visit. Treatment and management skills are optimised and the patient is given written instructions on how and when to increase treatment when asthma deteriorates (a written action plan).
A recent Cochrane review asked whether one can get the same benefits by doing less -by simply supplying a patient with a written action plan. 2 The review found that the literature was inconclusive. This doesn't mean that written action plans are not effective; it means that there is not enough evidence to be able to answer the question. The result of "no evidence of effect" is completely different to "evidence of no effect". 3, 4 This is a crucial distinction, as many systematic reviews find insufficient evidence to be able to assess a treatment. This is a statement about our ignorance rather than a statement about whether a treatment works or not.
The review also highlights the need to carefully evaluate the control intervention. For example, the control groups in two studies in the systematic review 2 received regular medical review, with assessment of severity and optimisation of inhaled steroid therapy. It is not surprising that these studies found it difficult to identify any additional effect of an action plan.
Cochrane systematic reviews conclude with recommendations for clinical practice that highlight effective treatments, 1 and with recommendations for research that indicate where more information is needed. 2 The review looking at just supplying patients with written action plans
